tiprankstipranks
Trending News
More News >
InteliCare Holdings Limited (AU:ICR)
:ICR
Australian Market

InteliCare Holdings Limited (ICR) AI Stock Analysis

Compare
104 Followers

Top Page

AU

InteliCare Holdings Limited

(Sydney:ICR)

Rating:34Underperform
Price Target:
InteliCare Holdings Limited's overall stock score reflects significant financial challenges, including persistent losses, negative equity, and cash flow difficulties. The absence of technical analysis data and a negative P/E ratio further highlight the company's unattractive investment profile. Major improvements in financial performance and strategic direction are needed to enhance stock appeal.

InteliCare Holdings Limited (ICR) vs. iShares MSCI Australia ETF (EWA)

InteliCare Holdings Limited Business Overview & Revenue Model

Company DescriptionIntelicare Holdings Limited engages in the sale of a predictive analytics hardware and software package for use in the aged care and health industries in Australia. The company offers InteliLiving for seniors and people with disability; and produces monitoring solution for seniors and at-risk individuals. Intelicare Holdings Limited was founded in 2016 and is headquartered in Leederville, Australia.
How the Company Makes MoneyInteliCare Holdings Limited generates revenue through the sale and subscription of its technology solutions, primarily the InteliLiving system. The company offers these products directly to consumers as well as to aged care providers and healthcare facilities. Revenue streams include one-time sales of hardware devices, such as sensors and monitoring equipment, and ongoing subscription fees for access to its software platform and data analytics services. Additionally, InteliCare may engage in partnerships with healthcare providers and institutions to expand its market reach and enhance product offerings, contributing to its revenue growth.

InteliCare Holdings Limited Financial Statement Overview

Summary
InteliCare Holdings Limited exhibits several financial challenges across its statements. The income statement shows persistent losses and negative margins, indicating difficulty in achieving profitability. The balance sheet is weak, with negative equity and a high liability position relative to assets, posing significant financial risk. The cash flow statement highlights ongoing cash flow difficulties, with consistent negative free cash flow and operating cash flow. Overall, the financial health of the company is poor, requiring significant improvements in revenue generation, cost control, and cash management to enhance financial stability and sustainability.
Income Statement
30
Negative
The income statement reveals consistent negative net income and gross profit over the years. The gross profit margin is negative due to higher costs than revenue. Revenue has shown volatility with a significant decline in the latest year, indicating an unstable growth trajectory. The net profit margin remains negative, suggesting ongoing challenges in achieving profitability. Overall, the income statement indicates significant room for improvement in financial performance.
Balance Sheet
25
Negative
The balance sheet shows a concerning negative stockholders' equity, indicating liabilities exceed assets, which is a significant risk factor. The company has a negative equity ratio, and the debt-to-equity ratio is not applicable due to negative equity. The return on equity is also negative, highlighting the company's inability to generate returns for shareholders. Overall, the balance sheet suggests financial instability and potential risks due to the high level of liabilities.
Cash Flow
35
Negative
The cash flow statement shows persistent negative operating cash flow, indicating challenges in generating cash from operations. Free cash flow is consistently negative, reflecting the company's struggle to cover capital expenditures and operational costs with its cash generation. The operating cash flow to net income ratio is not favorable, suggesting inefficiencies in turning income into cash. Overall, the cash flow statement highlights significant cash management challenges.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
658.63K280.29K404.35K429.85K363.12K267.54K
Gross Profit
-1.42M-1.79M-2.69M-2.75M-1.99M-1.27M
EBIT
-2.88M-3.11M-4.05M-4.75M-4.91M-2.60M
EBITDA
-2.22M-3.02M-2.92M-3.78M-4.24M-2.47M
Net Income Common Stockholders
-2.37M-2.26M-3.00M-3.93M-4.36M-2.55M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.26M834.20K1.94M2.27M2.67M4.20M
Total Assets
1.92M1.52M2.48M2.88M3.43M4.78M
Total Debt
390.19K545.39K726.57K18.25K85.16K144.58K
Net Debt
-869.48K-288.80K-1.21M-2.25M-2.59M-4.05M
Total Liabilities
1.31M1.69M1.53M1.34M842.64K753.63K
Stockholders Equity
604.64K-168.32K949.11K1.54M2.59M4.02M
Cash FlowFree Cash Flow
-1.84M-1.66M-3.11M-3.14M-3.86M-1.68M
Operating Cash Flow
-1.84M-1.66M-3.10M-3.10M-3.79M-1.57M
Investing Cash Flow
-3.10K0.00-14.35K-32.92K-74.79K-108.55K
Financing Cash Flow
1.69M555.65K2.78M2.73M2.34M5.83M

InteliCare Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
AUICR
34
Underperform
AU$2.93M-309.52%73.53%-7.35%
$25.67M-75.39%
$41.98M-185.67%
AUARA
61
Neutral
AU$92.60M20.302.75%2.08%11.31%
AUBDX
43
Neutral
AU$25.25M-104.23%-17.26%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ICR
InteliCare Holdings Limited
0.01
0.00
0.00%
CYYNF
Cynata Therapeutics Limited
0.12
-0.07
-36.84%
VHLUF
Vitasora Health
0.06
<0.01
20.00%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.04
-36.36%
AU:ARA
Ariadne Australia Limited
0.48
-0.01
-2.04%

InteliCare Holdings Limited Corporate Events

InteliCare Expands Aged Care Partnerships with New Trials and Deployments
Apr 30, 2025

InteliCare Holdings Ltd has announced a new commercial agreement with mecwacare to trial its InteliCare platform at the Trescowthick Centre in Victoria, marking a significant step in its strategy to expand partnerships with large aged care providers. The company is also progressing with deployments at Hardi Aged Care facilities, with integration into Hardi’s systems expected soon. These developments, alongside strategic partnerships with other health technology providers, position InteliCare to capitalize on growth opportunities in the evolving aged care sector, particularly with upcoming changes in the Aged Care Act and the Support at Home Program.

InteliCare Holdings Limited Reports Quarterly Cash Flow Results
Apr 30, 2025

InteliCare Holdings Limited reported its quarterly cash flow results, highlighting a net cash decrease from operating activities amounting to $447,000 and a slight reduction from investing activities at $2,000. Despite these operational cash flow challenges, the company experienced a positive cash flow from financing activities, resulting in a net increase in cash and cash equivalents for the period. This financial update suggests that while operational and investment cash flows are currently negative, the company is leveraging financing activities to maintain liquidity, which could impact its future strategic decisions and stakeholder confidence.

InteliCare Partners with mecwacare for Digital Transformation Trial
Apr 29, 2025

InteliCare Holdings Ltd has entered into a commercial agreement with mecwacare to trial its InteliCare solution at the Trescowthick Centre in Prahran, Victoria. This trial is part of mecwacare’s digital transformation strategy to become a leading technology-enabled care provider in Victoria. The three-month trial, which involves a $212k investment in hardware and implementation services, aims to assess the potential for broader deployment across mecwacare’s facilities. The collaboration is expected to enhance mecwacare’s service delivery and provide valuable insights into resident care, aligning with InteliCare’s commercialisation strategy and strengthening its position in the aged care sector.

InteliCare Reports Increased Losses and Decline in Asset Value for H2 2024
Feb 27, 2025

InteliCare Holdings Limited reported a 16.7% increase in its loss from ordinary activities after tax, amounting to $772,513 for the half-year ended December 31, 2024. The company did not declare any dividends during this period. The net tangible assets per ordinary security decreased from 0.39 cents in the previous period to 0.13 cents in the current reporting period, indicating a decline in asset value, which may impact investor confidence.

InteliCare Ensures Compliance with Performance Rights Issuance
Feb 11, 2025

InteliCare Holdings Limited has issued a notice under section 708A(5) of the Corporations Act regarding the issuance of performance rights that can be converted into fully paid ordinary shares. The company confirms compliance with relevant provisions of the Corporations Act and asserts that no information has been excluded from its continuous disclosure obligations. This announcement assures stakeholders of InteliCare’s adherence to legal requirements and transparency in its financial disclosures, which may impact investor confidence and market perception.

InteliCare Holdings: Director’s Interest Update
Feb 11, 2025

InteliCare Holdings Limited announced a change in the interests of its director, Neale Fong. The company disclosed that Fong has acquired 9,000,000 additional performance rights, increasing his total holding to 14,000,000 performance rights and maintaining 3,000,000 unlisted options. This move, approved by shareholders, signifies confidence in Fong’s leadership and could potentially influence investor perception positively given the increase in his stake in the company.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.